ATE239470T1 - Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen - Google Patents

Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen

Info

Publication number
ATE239470T1
ATE239470T1 AT94308467T AT94308467T ATE239470T1 AT E239470 T1 ATE239470 T1 AT E239470T1 AT 94308467 T AT94308467 T AT 94308467T AT 94308467 T AT94308467 T AT 94308467T AT E239470 T1 ATE239470 T1 AT E239470T1
Authority
AT
Austria
Prior art keywords
desynchronization
diseases
treatment
melatonin derivatives
melatonin
Prior art date
Application number
AT94308467T
Other languages
English (en)
Inventor
Michael Edward Flaugh
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE239470T1 publication Critical patent/ATE239470T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT94308467T 1993-11-18 1994-11-16 Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen ATE239470T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/154,903 US6180657B1 (en) 1993-11-18 1993-11-18 Melatonin derivatives for use in treating desynchronization disorders

Publications (1)

Publication Number Publication Date
ATE239470T1 true ATE239470T1 (de) 2003-05-15

Family

ID=22553300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94308467T ATE239470T1 (de) 1993-11-18 1994-11-16 Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen

Country Status (21)

Country Link
US (1) US6180657B1 (de)
EP (1) EP0656209B1 (de)
JP (1) JPH07196504A (de)
KR (1) KR950013509A (de)
CN (1) CN1100533C (de)
AT (1) ATE239470T1 (de)
AU (1) AU7777694A (de)
CA (1) CA2135710C (de)
CZ (1) CZ288834B6 (de)
DE (1) DE69432626T2 (de)
DK (1) DK0656209T3 (de)
ES (1) ES2197904T3 (de)
HU (1) HUT72070A (de)
IL (1) IL111579A (de)
NO (1) NO307364B1 (de)
NZ (1) NZ264893A (de)
PT (1) PT656209E (de)
RU (1) RU2160101C2 (de)
SG (1) SG77569A1 (de)
UA (1) UA35588C2 (de)
ZA (1) ZA948928B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748627A3 (de) * 1995-06-14 1997-05-21 Lilly Co Eli Melatoninagonisten zur Behandlung von gutartigen Hyperplasieformen der Prostata
US7674816B2 (en) * 2003-12-23 2010-03-09 Abraxis Bioscience, Llc Substituted melatonin derivatives, process for their preparation, and methods of use
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
EP2291406A4 (de) * 2008-05-19 2012-12-12 Takeda Pharmaceutical Zytotoxischer monoklonaler antikörper gegen krebs
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR20190006598A (ko) 2012-01-26 2019-01-18 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
MX2015007909A (es) 2012-12-18 2016-04-25 Vanda Pharmaceuticals Inc Tratamiento de trastornos del ritmo circadiano.
RU2533965C1 (ru) * 2013-07-04 2014-11-27 Государственное бюджетное учреждение здравоохранения "Самарский областной гериатрический центр" Способ нормализации циркадианных ритмов человека
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
RU2655813C1 (ru) * 2017-06-09 2018-05-29 Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства" Средство коррекции и профилактики состояний, вызванных нарушением суточных ритмов

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087444A (en) 1976-09-08 1978-05-02 Eli Lilly And Company Amides as ovulation inhibitors
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
EP0126630B1 (de) 1983-05-18 1987-09-16 Monash University Verwendung von Melatonin zur Herstellung eines Arzneimittels
US4614807A (en) 1984-10-04 1986-09-30 Eli Lilly And Company 6,7-dihalomelatonins
US4687763A (en) 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
AU616907B2 (en) 1987-08-17 1991-11-14 Whitby Research, Inc. Melatonin analogues
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
CA2116036A1 (en) * 1991-10-18 1993-04-29 F. Eugene Yates Device for the transdermal administration of melatonin
US5196435A (en) 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin

Also Published As

Publication number Publication date
DK0656209T3 (da) 2003-09-01
EP0656209A3 (de) 1995-10-11
RU2160101C2 (ru) 2000-12-10
KR950013509A (ko) 1995-06-15
CN1100533C (zh) 2003-02-05
JPH07196504A (ja) 1995-08-01
NO944340D0 (no) 1994-11-14
AU7777694A (en) 1995-05-25
SG77569A1 (en) 2001-01-16
IL111579A (en) 1999-10-28
IL111579A0 (en) 1995-01-24
PT656209E (pt) 2003-09-30
EP0656209B1 (de) 2003-05-07
CN1107700A (zh) 1995-09-06
NZ264893A (en) 1997-06-24
CZ276494A3 (en) 1995-07-12
NO944340L (no) 1995-05-19
EP0656209A2 (de) 1995-06-07
RU94041028A (ru) 1996-09-20
ES2197904T3 (es) 2004-01-16
CZ288834B6 (cs) 2001-09-12
DE69432626T2 (de) 2004-04-08
DE69432626D1 (de) 2003-06-12
HU9403299D0 (en) 1995-01-30
NO307364B1 (no) 2000-03-27
HUT72070A (en) 1996-03-28
CA2135710A1 (en) 1995-05-19
ZA948928B (en) 1996-05-10
CA2135710C (en) 2007-07-10
UA35588C2 (uk) 2001-04-16
US6180657B1 (en) 2001-01-30

Similar Documents

Publication Publication Date Title
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE69124293T2 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE69635213D1 (de) Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
DE3854121T2 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
ATE187442T1 (de) Tryptamine zur behandlung von störungen der circadianen rhythmik
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
DE69830811D1 (de) Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis
DE68906028T2 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0656209

Country of ref document: EP

REN Ceased due to non-payment of the annual fee